These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 2881450

  • 21. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ, Post B, Verschuur CV, de Bie RM.
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [Abstract] [Full Text] [Related]

  • 22. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa.
    Pal PK, Sathyaprabha TN, Tuhina P, Thennarasu K.
    Mov Disord; 2007 Feb 15; 22(3):420-4. PubMed ID: 17230476
    [Abstract] [Full Text] [Related]

  • 23. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M.
    Parkinsonism Relat Disord; 2009 Jan 15; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [Abstract] [Full Text] [Related]

  • 24. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 15; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 25. Levodopa in the early treatment of Parkinson's disease.
    Murata M.
    Parkinsonism Relat Disord; 2009 Jan 15; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [Abstract] [Full Text] [Related]

  • 26. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
    Melamed E.
    J Neural Transm Suppl; 1995 Jan 15; 45():57-60. PubMed ID: 8748609
    [Abstract] [Full Text] [Related]

  • 27. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S, Tolosa E, Burguera JA, Chacón J, Liaño H, Forcadell F.
    Clin Neuropharmacol; 1997 Feb 15; 20(1):67-76. PubMed ID: 9037575
    [Abstract] [Full Text] [Related]

  • 28. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL, Schmitt L, Bagheri H.
    Rev Neurol (Paris); 2003 Apr 15; 159(4):441-3. PubMed ID: 12773874
    [Abstract] [Full Text] [Related]

  • 29. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R, Lyons K, McGuire D, Silverstein P, Zwiebel F, Robischon M, Koller WC.
    Mov Disord; 1997 Sep 15; 12(5):677-81. PubMed ID: 9380047
    [Abstract] [Full Text] [Related]

  • 30. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
    Willis GL.
    Behav Brain Res; 2005 May 07; 160(1):148-60. PubMed ID: 15836910
    [Abstract] [Full Text] [Related]

  • 31. A study of salivary secretion in Parkinson's disease.
    Bagheri H, Damase-Michel C, Lapeyre-Mestre M, Cismondo S, O'Connell D, Senard JM, Rascol O, Montastruc JL.
    Clin Neuropharmacol; 1999 May 07; 22(4):213-5. PubMed ID: 10442250
    [Abstract] [Full Text] [Related]

  • 32. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
    Palmer SJ, Eigenraam L, Hoque T, McCaig RG, Troiano A, McKeown MJ.
    Neuroscience; 2009 Jan 23; 158(2):693-704. PubMed ID: 18722512
    [Abstract] [Full Text] [Related]

  • 33. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.
    Amino Acids; 2005 Mar 23; 28(2):157-64. PubMed ID: 15750845
    [Abstract] [Full Text] [Related]

  • 34. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease.
    Piboolnurak P, Lang AE, Lozano AM, Miyasaki JM, Saint-Cyr JA, Poon YY, Hutchison WD, Dostrovsky JO, Moro E.
    Mov Disord; 2007 May 15; 22(7):990-7. PubMed ID: 17443692
    [Abstract] [Full Text] [Related]

  • 35. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA, Dostrovsky JO, Moro E, Hodaie M, Lozano AM, Hutchison WD.
    Brain; 2009 Feb 15; 132(Pt 2):309-18. PubMed ID: 19050033
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST, Allbutt HN, Billing R, Radford J, Coster MJ, Kassiou M, Henderson JM.
    Brain Res Bull; 2009 Feb 16; 78(2-3):85-90. PubMed ID: 18822357
    [Abstract] [Full Text] [Related]

  • 37. [Hypersexuality during use of levodopa].
    van Deelen RA, Rommers MK, Eerenberg JG, Egberts AC.
    Ned Tijdschr Geneeskd; 2002 Nov 02; 146(44):2095-8. PubMed ID: 12448966
    [Abstract] [Full Text] [Related]

  • 38. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT.
    Clin Ther; 2005 Jan 02; 27(1):58-63. PubMed ID: 15763606
    [Abstract] [Full Text] [Related]

  • 39. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB, Bernardi G.
    Trends Pharmacol Sci; 2005 Jul 02; 26(7):341-4. PubMed ID: 15936832
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.